Novo Nordisk A/S (NVO) announced Monday that its Wegovy weight loss pill has officially launched in the United States, following FDA approval back in December 2025. If you've been following the weight loss drug wars, this is a pretty significant development in how these medications get delivered.
The clinical trial results tell an interesting story. When researchers looked at patients who stuck with the treatment throughout the study alongside a reduced-calorie diet and exercise regimen, the Wegovy pill delivered an average weight loss of about 17% (specifically 16.6%). That's compared to roughly 3% (2.7%) for those taking a placebo. In the real world, where not everyone stays on treatment, the numbers shift a bit: patients on Wegovy lost an average of about 14% (13.6%) of their body weight, while placebo participants lost around 2% (2.4%).
Getting Your Hands on the Pill
Novo Nordisk isn't messing around with distribution. The medication is rolling out through a broad network that includes major pharmacy chains like CVS (CVS) and Costco (COST). If you're more of a digital health person, it's also available through telehealth providers including Ro, LifeMD, Inc. (LFMD), Weight Watchers (WW), NovoCare Pharmacy, and GoodRx Holdings Inc. (GDRX), among others.
Here's where pricing gets interesting. For patients paying out of pocket, the starting dose of 1.5 mg will run you about $5 daily, which works out to $149 monthly. The 4 mg dose is also priced at $149 per month, but only through April 15, 2026. After that date, it jumps to $199 monthly. The highest strength pills will cost $299 per month. If you've got commercial insurance, Novo Nordisk's savings offer could bring your monthly cost down to as little as $25.
The pill comes in four dosage strengths: 1.5 mg (the starter dose), 4 mg, 9 mg, and 25 mg. For now, this approval is US-only.
Market Reaction and Technical Picture
So how did Wall Street respond to this news? Novo Nordisk (NVO) shares climbed 4.14% to $54.55 at the time of publication Monday. But before you get too excited, let's zoom out for perspective.
The stock is showing some short-term strength, trading above both its 20-day and 50-day simple moving averages. That's the good news. The less encouraging news? It's still sitting 8.4% below its 200-day simple moving average, which suggests the longer-term trend remains bearish.
The Relative Strength Index sits at 60.25, firmly in neutral territory. Translation: the stock isn't screaming overbought or oversold right now, which potentially leaves room for further upside if momentum continues building. The MACD indicator is trading above its signal line, another bullish sign that could attract additional buyers if the stock maintains its position above those shorter-term moving averages.
Traders are watching key levels closely. Support sits at $45.50, while resistance looms at $58.00. A hold at support could signal a bounce, while breaking through resistance might indicate a genuine trend reversal is underway.
The elephant in the room: Novo Nordisk shares have tumbled 35.61% over the past twelve months. That's a brutal decline that underscores why caution remains warranted despite recent short-term gains. The overall trend hasn't turned friendly just yet, even if this product launch injects some optimism into the story.
